Make your prediction
Buy inPayout
$100
$212
Buy prediction

About

If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2028, then the market resolves to Yes. GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part D sponsors through the Health Plan Management System. Where the White House or HHS makes the determination, the CMS document adopting it resolves this market, on the date of that document. The following do NOT resolve this market to YES: A CMS communication that discusses, studies or reports on such coverage. A proposed rule or a request for applications, which propose coverage rather than provide it. An action that considers the change and declines to make it. The Medicare GLP-1 Bridge, or extending or replacing it, because it sits outside the Part D benefit. An announcement covering only the Medicaid portion of the BALANCE Model. Coverage of a single drug, or of a subset of Part D enrollees, is sufficient. The announcement date governs, not the date coverage takes effect.

If CMS announces the addition of GLP-1 drugs for obesity to Part D before Jan 1, 2028, then the market resolves to Yes. GLP-1 drugs are already covered under Part D for type 2 diabetes, cardiovascular risk reduction and obstructive sleep apnea. Those indications are outside this market, which turns on coverage for obesity or chronic weight management. Only a completed CMS action that provides the coverage counts, such as a final rule, a finalized model design, or guidance to Part D sponsors through the Health Plan Management System. Where the White House or HHS makes the determination, the CMS document adopting it resolves this market, on the date of that document. The following do NOT resolve this market to YES: A CMS communication that discusses, studies or reports on such coverage. A proposed rule or a request for applications, which propose coverage rather than provide it. An action that considers the change and declines to make it. The Medicare GLP-1 Bridge, or extending or replacing it, because it sits outside the Part D benefit. An announcement covering only the Medicaid portion of the BALANCE Model. Coverage of a single drug, or of a subset of Part D enrollees, is sufficient. The announcement date governs, not the date coverage takes effect.

No volume detected, be the first!

Key stats

Expiry
Jan 1, 2028(492 days)
Interest
$14,664.18
Vol (24H)
$5,572.34↘ 32.28%
Total
$31K

Details

Timeline & rules

Timeline & payout

This market will close and expire when an outcome occurs. Otherwise, it closes by Jan 1, 2028, 4:59 AM GMT+0.

Trading prohibitions

The following are prohibited from trading this contract:
  • Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
  • Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.
Trending markets

A new era of Coinbase has begun

The future of money is here. Be one of the first to get access and try new features the moment they’re available.

Create an account now
FAQs

Discover more

Legal
Prediction markets are offered by Coinbase Financial Markets, a registered futures commission merchant with the Commodity Futures Trading Commission and a Member of the National Futures Association. Trading prediction contracts involve substantial risk and may result in the loss of your entire investment. Contracts pay out only if the specified event occurs. Trade only if you understand the product and believe it is appropriate for your financial situation and objectives.Certain content has been prepared by third parties not affiliated with Coinbase Financial Markets or any of its affiliates and Coinbase is not responsible for such content. Coinbase is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Information is provided for informational purposes only and is not investment advice. This is not a recommendation to buy or sell a particular digital asset or to employ a particular investment strategy. Coinbase makes no representation on the accuracy, suitability, or validity of any information provided or for a particular asset. Prices shown are for illustrative purposes only. Actual cryptocurrency prices and associated stats may vary. Data presented may reflect assets traded on Coinbase’s exchange and select other cryptocurrency exchanges. Past performance is not a reliable indicator of future results.